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Internal tandem duplication (ITD) mutations within
the FMS-like tyrosine kinase-3 (FLT3) render the
receptor constitutively active driving proliferation
and survival in leukemic blasts. Expression of FLT3-
ITD from the endogenous promoter in a murine
knockin model results in progenitor expansion and
a myeloproliferative neoplasm. In this study, we
show that this expansion begins with overprolifera-
tion within a compartment of normally quiescent
long-term hematopoietic stem cells (LT-HSCs),
which become rapidly depleted. This depletion is
reversible upon treatment with the small molecule
inhibitor Sorafenib, which also ablates the disease.
Although the normal LT-HSC has been defined as
FLT3 by flow cytometric detection, we demonstrate
that FLT3 is capable of playing a role within this
compartment by examining the effects of constitu-
tively activated FLT3-ITD. This indicates an impor-
tant link between stem cell quiescence/homeostasis
and myeloproliferative disease while also giving
novel insight into the emergence of FLT3-ITD muta-
tions in the evolution of leukemic transformation.
INTRODUCTION
Internal tandem duplications (ITD) in FMS-like tyrosine kinase-3
(FLT3) comprise a group of the most common molecular
mutations in acute myelogenous leukemia (AML) (Gilliland and
Griffin, 2002; Levis and Small, 2003; Stirewalt and Radich,
2003). Found in approximately 23% of AML cases, an ITD
mutation abrogates the negative regulatory function of the
juxtamembrane domain, rendering the receptor constitutively
active, independent of its natural ligand (Fenski et al., 2000; Kiyoi
et al., 1998; Mizuki et al., 2000). This oncogenic mutation
activates canonical receptor tyrosine kinase signaling, most346 Cell Stem Cell 11, 346–358, September 7, 2012 ª2012 Elsevier Iprominently via STAT5, RAS/MAPK, and PI3K, stimulating pro-
liferation and antiapoptotic pathways (Hayakawa et al., 2000;
Kiyoi et al., 1998; Mizuki et al., 2000; Tse et al., 2001).
The presence of an FLT3-ITD mutation is a poor prognostic
feature in AML, predicting increased relapse rates and reduced
overall survival (Fro¨hling et al., 2002; Kottaridis et al., 2001; Levis
and Small, 2003; Meshinchi et al., 2001; Nakao et al., 1996;
Thiede et al., 2002). Though there are many small molecule
FLT3 tyrosine kinase inhibitors (TKIs) in various stages of clinical
trials, responses have been largely heterogeneous and transient
(Grundler et al., 2003; Knapper et al., 2006; Levis et al., 2011;
Weisberg et al., 2002). After an initial response, patients relapse,
suggesting that leukemia-initiating stem cells may be escaping
TKI-induced cytotoxicity.
There has been increasing evidence linking FLT3-ITD with
leukemic stem cells (LSCs), including the presence of the muta-
tion within the CD34+/CD38 leukemia-initiating cell fraction
in most cases (Lapidot et al., 1994; Levis et al., 2005). The
FLT3-ITD mutation also remains present at relapse in most
cases, suggesting its presence in the cells that escape therapy
(Cloos et al., 2006; Shih et al., 2002). Furthermore, AML cases
that have the FLT3-ITDmutation were shown to have the highest
engraftment capacity in NOD/SCID mice (Lumkul et al., 2002;
Rombouts et al., 2000a, 2000b). Thus, understanding the role
of FLT3-ITD mutations in LSCs is of great therapeutic interest.
FLT3 is an important molecule in normal hematopoietic devel-
opment as well as in leukemia (Gilliland and Griffin, 2002). FLT3
is expressed on common lymphoid progenitors (CLPs) and
a minor fraction of common myeloid progenitors (CMPs) and is
implicated in dendritic cell development (D’Amico and Wu,
2003). Additionally, FLT3 is expressed during the early stages
of hematopoiesis, indicating a potential involvement in stem
cell function or maintenance. In murine hematopoiesis, where
cell surface marker expression during stages of differentia-
tion has been extremely well-defined, hematopoietic stem cell
(HSC) activity is restricted to a small subset of the Lin c-kit+
Sca-1+ (KSL) compartment (Ikuta and Weissman, 1992; Span-
grude et al., 1988; Okada et al., 1992; Katayama et al., 1993).
Yet, within this compartment, FLT3 is thought to be expressed
only on multipotent progenitor cells (MPPs) (Christensen andnc.
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have the lowest capacity for self-renewal and higher rates of
proliferation (Passegue´ et al., 2005), while the compartment
defined as FLT3 contains HSCs capable of short-term
(CD34+) or long-term (CD34) reconstitution of all hematopoietic
lineages (Morrison and Weissman, 1994; Osawa et al., 1996;
Randall et al., 1996). Thus the most primitive stem cell in the
murine hematopoietic hierarchy, the long-term HSC (LT-HSC),
has been classically defined by its lack of FLT3 expression.
FLT3 has been previously reported to be dispensable for
HSC maintenance and myeloid development (Sitnicka et al.,
2002) and FLT3 and FLT3-ligand (FL) knockout mice have only
minor defects in HSC function (Mackarehtschian et al., 1995;
McKenna et al., 2000). However, knockout studies fail to take
into account the effects of overlapping or compensatory path-
ways, and few studies to date have addressed the effects of
constitutive FLT3 activity on normal hematopoiesis or stem cell
function.
In order to determine whether the FLT3-ITD mutation affects
HSC function, our lab has generated a heterozygous FLT3-ITD
knockin mouse model that has an 18 bp insertion in the juxta-
membrane domain of murine FLT3 (Li et al., 2008). These
mice express the germline ITD mutation under control of the
endogenous murine FLT3 promoter and develop a myelopro-
liferative neoplasm (MPN) characterized by splenomegaly,
leukocytosis, and myeloid hypercellularity with a median
survival of 10 months. Here, we describe isolation of an
MPN-initiating stem cell within the signaling lymphocytic acti-
vation molecule (SLAM) compartment (LinCD48CD150+)
(Kiel et al., 2005) of FLT3-ITD knockin marrow that is capable
of full engraftment and complete recapitulation of the MPN
phenotype. Furthermore, we demonstrate that FLT3 transcripts
and FLT3 protein are detectable in the SLAM-defined LT-HSC
compartment and constitutive activation significantly perturbs
HSC quiescence/homeostasis. We find that FLT3-ITD ex-
pression under the endogenous promoter results in changes
in gene expression within the LT-HSC compartment including
molecules involved in increased proliferation and activation of
canonical FLT3 signaling pathways. Moreover, we demonstrate
in vivo restoration of normal HSC function and simultaneous
ablation of the MPN by treatment of mice with the FLT3
small molecule inhibitor Sorafenib. These data suggest a
previously unrecognized role of FLT3 in LT-HSC homeostasis
and demonstrate an intrinsic link between normal stem cell
quiescence/homeostasis and MPN development as well as
provide novel insights into the occurrence of FLT3 mutations
in leukemogenesis.
RESULTS
Physiological Expression of FLT3-ITD Results
in Changes in Composition of the Hematopoietic
Stem-Progenitor Cell Compartment
Bone marrow was harvested from mice heterozygous for the
FLT3-ITD mutation under the control of its endogenous
promoter. When stained for cell surface marker expression,
FLT3-ITD bone marrow consistently displayed a 2- to10-fold
expansion in the total number of lineage progenitor cells as
compared to wild-type (WT) littermate controls (Figures 1A, 1B,Cell Sand 1F). Within this expanded compartment, FLT3-ITD marrow
showed increased numbers of cells expressing both c-kit and
Sca-1, resulting in an approximaetly 4- to 8-fold increase in total
number of KSLs—a population enriched for multipotent HSCs
(Figures 1C and 1D) (Spangrude et al., 1988; Okada et al.,
1992; Katayama et al., 1993). Upon further breakdown of the
KSL compartment by FLT3 and CD34 expression, FLT3-ITD
mice appeared to have an increase in the frequency of MPPs
as well as an uncharacterized population of cells expressing
Lin Kit+Sca-1+ FLT3+CD34 not observed at a significant
frequency in WT littermates (Figure 1E).
An alternative method for phenotypic identification of HSCs
eliminates FLT3 as a necessary surface marker by utilizing
SLAM marker expression to identify these rare cells. SLAM-
defined HSCs (Lin CD48CD150+) have previously been
described as highly enriched for long-term engraftment capacity
(Kiel et al., 2005). Strikingly, FLT3-ITD mice consistently dis-
played a 2- to 5-fold decrease in this SLAM population despite
increases observed in total bone marrow cellularity (Figures
1F–1H). This decrease was even greater for the KSL-SLAM
compartment (Figures 1I and 1J), which is believed to be even
further enriched for LT-HSCs (Kiel et al., 2005). This observed
progenitor expansion with concomitant decrease in phenotypic
LT-HSCs suggests that the expression of FLT3-ITD might per-
turb normal HSC homeostasis.
Another method for HSC identification is the frequency of
side population (SP) cells as determined by MDR1-mediated
Hoechst dye efflux, commonly associated with functional HSC
activity (Goodell et al., 2005). Again FLT3-ITD bone marrow dis-
played a consistent 5-fold reduction in number of SP-defined
HSCs (Figures 2A and 2B). When they were examined for over-
lap with cell surface marker phenotype, we observed that
a significantly smaller proportion of FLT3-ITD KSL cells were
SP cells, as compared to results in WT littermate controls (Fig-
ure 2C), suggesting that fewer FLT3-ITD KSLs were functional
stem cells.
FLT3-ITD Expression Results in an Observed Reduction
in HSC Activity
To investigate the functional effects of the FLT3-ITD mutation on
HSCs, we transplanted several cell surface marker-defined
hematopoietic populations. Unfractionated, lineage-depleted,
and KSL bone marrow populations from FLT3-ITD mice demon-
strated decreased engraftment capacity in comparison to WT
marrow (Figure 2D). The presence of the ITD mutation did not
confer any abnormal long-term engraftment capacity to any
progenitor population examined, including CMPs, GMPs,
MPPs, ST-HSCs, or the uncharacterized KSL FLT3+CD34
compartment (Table S1 available online).
To explore the possibility that FLT3-ITD expression was
affecting engraftment primarily by altering the homing ability
of HSCs, intrafemoral injections were performed to bypass
the need for HSCs to traffic to the bone marrow. As seen
with intravenous injection, intrafemorally injected FLT3-ITD
Lin cells resulted in significantly reduced engraftment levels
when compared to WT controls (Figure S1 available online).
These data suggest that homing to the bone marrow is
not the primary mechanism behind FLT3-ITD engraftment
defects.tem Cell 11, 346–358, September 7, 2012 ª2012 Elsevier Inc. 347
Figure 1. Expression of FLT3-ITD from
the Endogenous Promoter Disrupts HSPC
Composition in Knockin Mice
Representative flow cytometric analyses and
quantification of HSPC populations in bone
marrow from WT and FLT3-ITD littermates.
(A and B) Lineage negative compartment.
(C and D) KSLs (Lin c-kit+ Sca-1+).
(E) LT-HSC, ST-HSC, and MPP populations by
CD34 and FLT3 expression within the KSL pop-
ulation.
(F) Total bone marrow cellularity.
(G and H) SLAM populations (Lin CD150+
CD48).
(I and J) KSL-SLAM populations (Lin c-kit+
Sca-1+ CD150+ CD48). Data is representative
of three independent experiments. *p < 0.05.
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the SLAM Compartment
As SLAM-defined HSCs have been previously shown to be
highly enriched for cells with high long-term engraftment
capacity (Kiel et al., 2005), we hypothesized that the observed
engraftment defect may be due to the depletion of this SLAM
population (Figures 1G and 1H). Once sorted by lineage and
CD150 and CD48 expression, WT and FLT3-ITD SLAM cells
demonstrated equivalent engraftment capacity, suggesting
that in this model, SLAM cells best represent the functional
HSC (Figure 3A).
We next sought to determine whether FLT3-ITD SLAM cells
were capable of recapitulating theMPN observed and previously
reported in mice harboring the knockin mutation (Li et al., 2008).
Transplant recipients of either FLT3-ITD orWT sorted SLAMcells
were sacrificed 8 weeks posttransplant and examined for signs348 Cell Stem Cell 11, 346–358, September 7, 2012 ª2012 Elsevier Inc.of disease. FLT3-ITD SLAM recipients
exhibited both splenomegaly andmyeloid
expansion (Figures 3B and 3D). In addi-
tion, transplant recipients recapitulated
the stem cell immunophenotypic abnor-
malities observed in primary FLT3-ITD
knockin animals. FLT3-ITD SLAM recipi-
ents displayed a significant expansion in
lineage and myeloid progenitor cells, as
observed in the donor mice (Figures 3C
and 3D). Interestingly, despite receiving
an equivalent number of donor SLAM
cells, FLT3-ITD recipients demonstrated
a 2- to 4-fold depletion of the SLAM
compartment by 8 weeks posttransplant
(Figure 3E). These data reveal that FLT3-
ITD SLAM cells have the ability not only
to engraft, but also to autonomously
lead to the development of a MPN.
Flt3 mRNA and FLT3 Protein Are
Present at Detectable Levels in
Long-Term Engrafting SLAM Cells
In mice, the LT-HSC has been classically
defined as having a LinKit+Sca-1+CD34FLT3 immunophenotype (Christensen and Weissman,
2001; Osawa et al., 1996). Due to the observed defect in engraft-
ment in the FLT3-ITD knockin mice and the correlated depletion
of the SLAM compartment, we hypothesized that although FLT3
surface protein may not be abundant enough for detection by
flow cytometry in LT-HSCs, low levels of expression may still
play a role in stem cell homeostasis. To determine whether
FLT3 was transcribed in the long-term engrafting and MPN-
initiating stem cell, SLAM cells from both WT and FLT3-ITD
mice were sorted and Flt3 transcript levels were quantified by
qRT-PCR. Flt3 transcripts were detectable in both WT and
FLT3-ITD SLAM cells, with an approximately 4-fold increase in
Flt3 mRNA expression in the FLT3-ITD SLAM compartment
(Figure 4A).
As FLT3 protein is thought to be absent or undetectable on the
cell surface of classically defined primitive LT-HSCs, we were
Figure 2. FLT3-ITD Bone Marrow Demonstrates Reduced Side Population and HSC Function
(A) Representative flow analysis of Side Population cells by Hoechst dye efflux in WT and FLT3-ITD mice (n = 6).
(B) Verapamil control.
(C) Overlap of Hoechst efflux activity within KSL populations (n = 6).
(D) Lethally irradiated recipient mice (CD45.1) were injected with CD45.2 bone marrow cells from WT or FLT3-ITD donors. For total bone marrow (tBM)
experiments 23 106 tBM donor cells were injected with 53 105 CD45.1 helper cells. For Lin and KSL transplants, 13 105 Lin cells or 5,000 KSLs were injected
with 13 106 WT CD45.1 tBM helper cells (n = 5 mice for each group). Mice were bled at 4 weeks posttransplant and analyzed for the ratio of CD45.2 to CD45.1 in
peripheral blood. Data is representative of three independent experiments. *p < 0.05, **p < 0.01, and not significant (ns).
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resulted in detectable FLT3 protein. When we measured the
levels of total FLT3 protein (including intracellular) in the SLAM-
defined HSC compartments of WT and FLT3-ITD mice, we
were able to detect FLT3 protein in a fraction of both SLAM
compartments (Figure 4B).
The Effect of FLT3-ITD on LT-HSC Homeostasis
Is Cell Autonomous
We next sought to determine whether our observed FLT3-ITD
phenotype in the LT-HSC was due to its direct expression
within these primitive stem cells or if the effect was an indirect
microenvironmental one (i.e., through cytokine/growth factor
release from FLT3-ITD expressing cells in the bulk bone marrow
or stromal environment). We transplanted recipient mice with
a mixture of WT and FLT3-ITD Lin bone marrow cells that
resulted in approximately equal numbers of WT and FLT3-ITD
SLAM cells. We could then examine the effects on both stem
cell populations in a single environment (in the presence of
both WT and FLT3-ITD marrow). At 10 weeks posttransplant,Cell Sbone marrow from these mice was examined for the presence
of WT (CD45.1) and FLT3-ITD (CD45.2) SLAM cells. Strikingly,
only the FLT3-ITD SLAM cells were depleted, with the frequency
of WT SLAM cells remaining at a normal level (Figure 4C). Within
a single recipient, WT SLAM cells were present at frequencies
ranging from 3- to 20-fold higher than FLT3-ITD SLAM cells
(Table S2), suggesting that the observed SLAM depletion was
a direct, cell autonomous effect.
Constitutive FLT3 Activation Leads to Increased
Proliferation within the Normally Quiescent LT-HSC
Compartment
In an effort to determine the mechanism of FLT3-ITD-driven
SLAM cell depletion, we hypothesized that the oncogenic muta-
tion may drive these normally quiescent cells to proliferate. To
further investigate, we measured HSC proliferation rates in WT
and FLT3-ITD bone marrow through in vivo BrdU incorporation
assays. Bone marrow was harvested 4 hr post BrdU injection
and costained with cell surface markers to determine prolifera-
tion in multiple hematopoietic stem-progenitor cell (HSPC)tem Cell 11, 346–358, September 7, 2012 ª2012 Elsevier Inc. 349
Figure 3. Transplantation of SLAM Cells Recapitulates MPN Phenotypes
(A) Transplantation of either 500WT or ITDCD45.2 SLAM sorted cells (LinCD150+CD48) into lethally irradiated recipients (CD45.1) with 100,000 Sca-1 depleted
CD45.1 helper cells (n = 4 for WT mice, n = 5 ITD mice). Peripheral blood was measured for CD45.2 contribution at each time point shown. These data are
representative of two independent experiments.
(B) Representative spleen weights from primary transplants.
(C) Percent of WBM staining negative for Lineage markers.
(D) Percent of WBM positive for myeloid markers Mac-1 and Gr-1.
(E) SLAM cell percentage of WBM. Mice were sacrificed and analyzed for disease progression 8 weeks posttransplant. These data are representative of two
independent experiments with n = 4 mice. *p < 0.05 and **p < 0.01.
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ITDmice unexpectedly displayed decreased BrdU incorporation
in this fraction (Figures 5A–5C). In striking contrast, however,
subsets more highly enriched for LT-HSCs from FLT3-ITD mice
demonstrated an unusually high level of BrdU incorporation.
FLT3-ITD KSLs and KSL-SLAM cells had a greater than 2-fold
increase in BrdU incorporation rate over those of WT controls.
To further establish whether the FLT3-ITD mutation was driving
normally quiescent HSCs to proliferate, we examined cell cycle
status by measuring PI staining in stem cell subsets. While
WT and FLT3-ITD Lin progenitors demonstrated equivalent
numbers of cells in S+G2/M phase, FLT3-ITD SLAM cells
showed significant increases in cycling cells as compared to
WT littermates (Figure 5D).
Downstream Targets of FLT3 Are Abnormally Activated
in FLT3-ITD SLAM Cells
To further validate that the observed expression of FLT3-ITD
in the HSC resulted in a functional signal, we measured the
activation of known FLT3 downstream signaling molecules in
these cells. As FLT3-ITD signaling is known to activate the
STAT5 transcription factor (Hayakawa et al., 2000), wemeasured
the expression of Stat5 targets by qRT-PCR in FLT3-ITD SLAM
cells (Basham et al., 2008). When compared to WT SLAM cells,
several Stat5 targets were significantly overexpressed in the350 Cell Stem Cell 11, 346–358, September 7, 2012 ª2012 Elsevier IFLT3-ITD SLAM compartment—most prominently Fos, JunB,
Mkp-1, andSocs3 (Figure 5E). Additionally, we examined several
genes that have been found to be upregulated by FLT3-ITD
signaling in CD34+ cells transduced with FLT3-ITD (Kim et al.,
2007; Li et al., 2007). We found that Pim1 was overexpressed
an average of 5-fold within the FLT3-ITD SLAM compartment
compared to WT SLAM cells. Finally, a positive regulator of
cell cycle progression, Cyclin F, was found to be overexpressed
in the FLT3-ITD SLAM compartment, while negative cell cycle
regulator p57 was downregulated. These data indicate that
constitutively activated FLT3 alters gene expression patterns
and proliferation status within the most primitive compartment
of HSCs.
Inhibition of FLT3-ITD Signaling Using the Small
Molecule Inhibitor Sorafenib Leads to Restoration
of Normal Stem Cell Activity and Ablation of the MPN
As the depletion of LT-HSCs in the ITD mice is driven by FLT3-
ITD signaling, we hypothesized that attenuating FLT3-ITD
signaling may restore normal stem cell activity in the knockin
mice. Sorafenib has been shown to have significant activity
against FLT3 (Auclair et al., 2007; Zhang et al., 2008), and is
approved for use in targeting Raf-1 in renal cell carcinoma
(Escudier et al., 2007). Several clinical trials involving Sorafenib
have shown promising activity in AML patients with FLT3nc.
Figure 4. FLT3 Is Detected in SLAM Cells and Is Capable of Exerting Functional Effects in LT-HSCs
(A) Flt3 expression measured by quantitative PCR in sorted SLAM cells from WT or FLT3-ITD mice. Results shown are the average of three independent
experiments ±SEM, normalized to internal control RPS16. Data is normalized to baseline Flt3 expression in WT SLAM cells. p < 0.01.
(B) Representative flow analysis of Lin and SLAM cell compartment for expression of total FLT3 protein (surface and intracellular). Results shown are compared
to isotype controls. Data is representative of three independent experiments. p < 0.01 (Lin), p < 0.05 (SLAM).
(C) Representative flow analysis of SLAM cell frequency in bone marrow of chimeric mice containing both WT (CD45.1) and FLT3-ITD (CD45.2) bone marrow
(n = 4 mice). Data is representative of three independent experiments; see also Table S2. p < 0.05.
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2010b; Crump et al., 2010). Sorafenib also appears to have
selective inhibitory effects on mutant FLT3-ITD over WT FLT3
(Zhang et al., 2008). Treating mice with Sorafenib has been
shown to induce regression of MV4;11 (a human AML cell line
expressing FLT3-ITD) tumors in nude mice (Auclair et al., 2007).
To determine whether the loss of LT-HSCs observed in FLT3-
ITD mice could be prevented, we sought to attenuate FLT3-ITD
signaling early in development. WT females were bred to males
heterozygous for the mutation, and pregnant mothers were
treated with Sorafenib (20mg/kg) beginning at day 15 of preg-
nancy.Mothers were continually treated during a 2-week feeding
period after giving birth, enabling pups to receive Sorafenib
doses through breast milk. At 2 weeks of age, FLT3-ITD pups
from untreated mothers displayed splenomegaly (Figure 6A),
myeloid expansion (Figures 6B and 6C), a 5-fold reduction in
KSL-SLAM cells, and a 2-fold reduction in SLAM cells. In
contrast, FLT3-ITD pups from treated mothers displayed no
clinical signs of disease and their bone marrow containedCell Sequivalent numbers of SLAM and KSL-SLAM cells to those of
WT littermates (Figures 6D and 6E).
Having demonstrated that stem cell numbers could be
preserved and MPN prevented if mice were treated during
development of the hematopoietic system, we next examined
whether HSC numbers and function could be restored after the
MPN was already established in adult mice. Adult heterozygous
mice were treated with 10 mg/kg Sorafenib for 2 weeks. Post-
treatment, these mice demonstrated near complete resolution
of the MPN phenotype, including a reduction in spleen size (Fig-
ure 7A) and a decrease in progenitor numberswithin the Lin and
KSL compartments to levels comparable to those inWT controls
(Figures 7B and 7C). Strikingly, the numbers of SLAM and
KSL-SLAM cells were also largely restored to the levels of WT
controls (Figures 7D and 7E). Histopathology of the BM and
spleen also demonstrated the restoration of cellularity and
architecture in these tissues in the FLT3-ITD treated mice (Fig-
ure 7G). In spleens from FLT3-ITD mice treated with Sorafenib,
we observed reductions in overall cellularity, nucleated cells,tem Cell 11, 346–358, September 7, 2012 ª2012 Elsevier Inc. 351
Figure 5. FLT3-ITD HSCs Demonstrate Increased Proliferation and Cell Cycle Entry
(A and B) Bone marrow was harvested from (A) WT and (B) FLT3-ITD mice 24 hr after BrdU injection. FACS plots represent two or three pooled mice and are
representative of data from two independent experiments. Lineage-depleted marrow was stained for KSL and SLAM markers as well as for BrdU incorporation.
(C) Quantification of BrdU incorporation in Lin, KSL, and KSL-SLAM stem cell subsets.
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The marrow of FLT3-ITD treated mice displayed decreased
cellularity, collapsing venous sinuses, and restoration of the
number of mature red blood cells in the marrow (Figure 7G).
Thus, small molecule inhibition of FLT3-ITD simultaneously led
to reversal of disease phenotype and restoration of normal
stem cell homeostasis in adult mice.
To ensure that the observed increase in phenotypic SLAM
cells was also indicative of a restoration of stem cell function,
Lin progenitors from treated and untreated WT and FLT3-ITD
mice were transplanted into lethally irradiated recipients.
Recipient mice were treated with 10 mg/kg Sorafenib for an
additional 2 weeks after irradiation to continue inhibition of
FLT3-ITD signaling during the engraftment period. At 4 weeks
posttransplant, in contrast to untreated FLT3-ITD marrow,
treated FLT3-ITD Lin bone marrow demonstrated greatly
increased engraftment capacity, equivalent to that of WT con-
trols (Figure 7F).
DISCUSSION
This model, in which the FLT3-ITD mutation is knocked in to the
murine gene under the control of its endogenous promoter,
provides a powerful tool to study the function of constitutive
FLT3 activity in the murine hematopoietic system. Our results
demonstrate that the FLT3-ITD mutation results in major pertur-
bations in HSPC composition as well as functional defects
in stem cell homeostasis and reconstitution capacity. The
observed functional alterations in the LT-HSCs point to a previ-
ously unrecognized role for FLT3 in governing the dynamics of
this population.
These results are somewhat surprising in light of the previous
paradigm that FLT3 protein is undetectable by flow cytometry
on the cell surface of LT-HSCs. FLT3 knockout mice display
minor defects in stem cell fitness, revealed only through serial
competitive transplant experiments (Mackarehtschian et al.,
1995). Additionally, previous studies seem to rule out FLT3 and
its ligand as critical regulators of HSC maintenance and post-
transplantation expansion in FLT3 and FL knockout mice
(Buza-Vidas et al., 2009). However, FLT3 signaling is known to
partially overlap with other receptors (i.e., c-kit) and compensa-
tory regulation by these other pathways may explain why the
role of FLT3 in stem cell function has been masked in previous
knockout studies.
MPPs with detectable surface FLT3 are thought to have less
self-renewal capacity, yet give rise to all hematopoietic lineages
including myeloid progenitors as well as lymphoid-primed MPPs
(Christensen and Weissman, 2001; Adolfsson et al., 2001; Boyer
et al., 2011). However, recent data from FLT3-Cre-driven fate
mapping has suggested that Flt3 transcriptional activity initiates
in the phenotypic KSL-SLAM HSC compartment (Buza-Vidas
et al., 2011). This raises the possibility that FLT3 can be ex-
pressed and potentially functional without abundant cell surface(D) PI staining of Lin progenitors or SLAM cells from one representative experim
S+G2/M phase. Data is representative of three independent experiments and su
(E) Quantitative PCR of predicted FLT3 targets, Stat5 targets, and cell cycle regula
and results shown are the average of three independent experiments ±SEM. All re
expression in WT SLAM cells. *p < 0.05, **p < 0.01, and not significant (ns).
Cell Sprotein present, as the limit of sensitivity for conventional FACS
detection is typically 2,000 molecules/cell (Zola, 2004). These
and our data do not preclude the possibility that these FLT3+
cells within the SLAM and KSL-SLAM compartments are non-
self-renewing progenitors. Rather, our results demonstrate that
Flt3 mRNA, total FLT3 protein (including intracellular), and acti-
vation of FLT3 signaling are all detectable within SLAM-defined
LT-HSCs. These results are congruent with the previous para-
digm defining LT-HSCs as FLT3, in that FLT3 cell surface
protein may not be present at a level detectable by flow cytom-
etry in these cells. Ourmousemodel demonstrates a comparison
of FLT3 constitutive activity in the HSC to that of genetically
identical siblings and illustrates that FLT3 is capable of playing
a functional role in this compartment, despite its low expression
levels.
WT FLT3 must homodimerize in the presence of ligand to
propagate downstream signaling. FLT3-ITD molecules, in
contrast, are constitutively active and can homodimerize or het-
erodimerize with WT molecules, resulting in activation of down-
stream effectors in the absence of ligand (Kiyoi et al., 2002,
Choudhary et al., 2009). This allows even small amounts of the
activated mutant receptor to exert strong effects on signaling.
This property of FLT3-ITD may explain the strong phenotype
seen in our mouse model despite low levels of cell surface
protein, as well as why the role of FLT3 in LT-HSCs would be
difficult to observe in the absence of a constitutively active
mutant.
Our model demonstrates that FLT3-ITD is acting within the
LT-HSC itself as opposed to exerting its effects on this popula-
tion through the microenvironment. After a mixed bone marrow
transplant, we produced recipients harboring both WT and
FLT3-ITD hematopoiesis within a single bone marrow environ-
ment. We observed depletion of only the ITD SLAM cells and
not the WT SLAM cells from this mixed environment. These
data suggest that the depletion of the SLAM compartment in
ITD mice is not the result of secondary environmental effects,
but rather a direct effect of the mutation in this compartment.
As further evidence of FLT3 activity within this extremely rare
LT-HSC population, we noted a significant increase in known
downstream signaling, including increased expression of Stat5
targets and cell cycle promoters, along with a decrease in cell
cycle inhibitor p57. The result of FLT3-ITD signaling in the LT-
HSC is a depletion of the pool of primitive stem cells. This onco-
genic mutation disrupts HSC homeostasis, driving increased
proliferation within this normally quiescent compartment and
causing a greater proportion of HSCs to enter the cell cycle.
This result is even more striking within the context of an overall
decreased proliferation rate in FLT3-ITD Lin bulk progenitors.
The general decreased proliferation may be due to negative
feedback signals resulting from an abundance of myeloid
progenitors present in the blood and marrow. Aberrant overpro-
liferation of the normally quiescent stem cell compartment
leads to HSC exhaustion (Orford and Scadden, 2008; Akalaent of WT versus FLT3-ITD mice. Gates shown represent percentage of cells in
mmarized with SEM.
tors. SLAM cells were sorted from pools of three or four WT or FLT3-ITD mice,
adings were normalized to internal control RPS16 and set to a baseline of 1 for
tem Cell 11, 346–358, September 7, 2012 ª2012 Elsevier Inc. 353
Figure 6. Early Treatment with Sorafenib Prevents MPN and Preserves Stem Cell Numbers
WT females were bred to a heterozygous FLT3-ITD male and treated with Sorafenib starting at E.15 through weaning of pups at 2 weeks of age. Data is
representative of three independent experiments.
(A) Spleens harvested from untreated pups versus those treated with Sorafenib. FLT3-ITD mice are noted with (#). Spleen weight is quantified by genotype in
right panel.
(B–E) Quantification of percentage of bone marrow comprising (B) Lin progenitors, (C) KSLs, (D) SLAM cells, or (E) KSL-SLAM cells in treated versus untreated
WT and FLT3-ITD mice. *p < 0.05 and **p < 0.01.
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FLT3-ITD Disrupts HSC Quiescence/Homeostasisand Clarke, 2006). In our model, it also results in the overpro-
duction of various lineages (particularly of myeloid origin)
that give rise to our MPN phenotype, highlighting once again
the essential link between quiescence, HSC homeostasis, and
disease progression.
When FLT3-ITD signaling is attenuated through treatment
with the small molecule inhibitor Sorafenib, the intricate link
between stem cell homeostasis and disease becomes even354 Cell Stem Cell 11, 346–358, September 7, 2012 ª2012 Elsevier Imore apparent. The restoration of stem cell numbers after only
2 weeks of treatment demonstrates the surprising resiliency
and plasticity of HSCs. Although LT-HSCs normally divide only
once every 5 months, there is growing evidence that this
dynamic population is capable of rapidly responding to injury
and then quickly returning to a largely quiescent steady state
(Wilson et al., 2008). The rapid response of FLT3-ITD-harboring
LT-HSCs to Sorafenib treatment reveals a surprising level ofnc.
Figure 7. Treatment of Adult Mice with Sorafenib Restores Stem Cell Activity and Reverses Signs of Disease
Adult mice 8 weeks of age were treated daily with Sorafenib (sb) for 2 weeks. Data represents averages of four mice per group and is representative of two
independent experiments.
(A) Quantification of spleen weight for treated versus untreated adult mice.
(B–E) Quantification of percentage of bone marrow comprising (B) Lin progenitors, (C) KSLs, (D) SLAM cells, or (E) KSL-SLAM cells in treated versus untreated
adult mice.
(F) 100,000 CD45.2 lineage-depleted donor cells from treated or untreated WT or FLT3-ITD mice were transplanted along with 1 3 106 CD45.1 whole bone
marrow helper cells into lethally irradiated CD45.1 recipients. Peripheral blood was analyzed for percent donor engraftment 4 weeks posttransplant. p value of
WT and WT+sb was not significant (p > 0.05).
(G) H&E histopathology showing bone marrow (top row) and spleen (bottom row) architecture in treated and untreated adult WT and FLT3-ITD mice (WP =White
Pulp, RP = Red Pulp). *p < 0.05, **p < 0.01, and not significant (ns). Scale bars represent 50 mm and 10 mm for bone marrow and spleen, respectively.
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FLT3-ITD Disrupts HSC Quiescence/Homeostasissensitivity within the hematopoietic system. While FLT3 inhibi-
tion appears nontoxic to normal HSCs, we demonstrate that
Sorafenib is capable of targeting signaling within a rare popula-
tion of MPN-initiating SLAM cells in FLT3-ITD mice, indicating
the drug may be capable of targeting FLT3-ITD-containing
leukemic stem cells in AML patients as well.
While the role of FLT3 is less completely understood in human
hematopoiesis than in murine hematopoiesis, there is growing
evidence that FLT3 is present in both normal human HSCs and
AML LSCs (Kikushige et al., 2008; Levis et al., 2005). While
FLT3-ITDmutations are present in only about 5% of MDS cases,
the mutation is more frequently observed at the time of progres-
sion to AML, suggesting a role in transformation from MDS to
AML (Cloos et al., 2006; Shih et al., 2002; Pinheiro et al., 2008).
In the majority of AML cases, ITD mutations are present in de
novo disease with normal cytogenetics. These patients achieveCell Ssimilar remission rates to patients lacking the mutation, yet
FLT3-ITD patients are more likely to relapse, with a median
survival of less than 5 months postrelapse (Kottaridis et al.,
2001; Fro¨hling et al., 2002; Thiede et al., 2002; Ravandi et al.,
2010a; Levis et al., 2011). While FLT3-ITD alone does not fully
transform a cell to leukemia, growing evidence implicates this
mutation in the process of disease progression and LSC survival
and maintenance (Pinheiro et al., 2008; Yoshimoto et al., 2009).
We and others have shown that the combination of FLT3-ITD
with other oncogenic mutations can lead to the development
of a full-blown leukemia in mice (Stubbs et al., 2008; Greenblatt
et al., 2012), lending credence to the ‘‘two-hit’’ model of leuke-
mogenesis (Gilliland and Griffin, 2002). Our knockin model
studies suggest that one reason FLT3-ITD mutations are not
sufficient to induce a leukemia may be due to ITD-driven deple-
tion of the LT-HSC compartment. Thus, ITD mutations in antem Cell 11, 346–358, September 7, 2012 ª2012 Elsevier Inc. 355
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FLT3-ITD Disrupts HSC Quiescence/Homeostasisotherwise normal LT-HSC are unlikely to result in leukemia as
they would instead lead to rapid elimination of the clone, with
strong selective pressure against stem cells bearing this
mutation. In other stages of development or in the presence of
additional genetic lesions, however, FLT3-ITD may instead
cooperate to confer proliferative advantages (Stubbs et al.,
2008). This may explain why FLT3 mutations do not seem to
be early hits in primitive HSC compartments but rather acquired
in later stages of leukemogenesis in human AML. This may also
explain recent findings suggesting that FLT3-ITD mutations are
not present in human preleukemic clones, further implicating
this mutation as a secondary hit (Jan et al., 2011, Blood,
abstract).
Novel insight into the role of FLT3 activating mutations in the
overall etiology of transformation to leukemia may reveal new
potential therapeutic strategies. In order to effectively target
this molecule in AML patients, it becomes necessary to consider
the function of FLT3 in both disease development and stem cell
maintenance, as well as the oncogenic dependence of leukemic
blasts on FLT3 signaling for continued survival and proliferation.
In LSCs strongly dependent on FLT3 signaling, inhibition may
allow opportunities for blast clearance. In other cases FLT3 inhi-
bition with Sorafenib may simply return LSCs to a more normal
proliferative state. As such, in the case of human disease,
FLT3 may be considered for long-term combination therapy or




Generation of mice harboring an FLT3-ITD mutation knocked in to the endog-
enous FLT3 locus has been previously described (Li et al., 2008). The mice
used in these experiments were bred with a CMV-Cre line to flox out the
neo selection cassette. Except for Sorafenib-treated pups that were 2 weeks
of age, all mice were evaluated at 6–10 weeks of age with age-matched,
littermate controls. All experiments were performed in accordance with
IACUC-approved protocols.
Bone Marrow Isolation
Bone marrow was harvested by crushing tibias, femurs, hips, and spine of
each mouse with a mortar and pestle (Lo Celso and Scadden, 2007). Red
blood cell lysis was performed according to the manufacturer’s protocol using
RBC lysis buffer (eBioscience).
Transplantation
Congenic C57BL/6 CD45.1+ recipient mice were irradiated with a single dose
at a lethal (10 cGy) level, deliveredR4 hr before injections. For in vivo intrafe-
moral injections, cells were injected into the femoral cavity of anesthetized
mice with a Hamilton needle (Sigma Aldrich). Sca-1-depleted helper cells
were obtained from double positive CD45.1+CD45.2+ bone marrow flushed
from femurs stained with Sca-1-APC and depleted using anti-allophycocyanin
(APC) microbeads (Miltenyi Biotech) bound to LD columns (Miltenyi Biotech).
Similarly, lineage depletions were conducted using biotinylated monoclonal
antibodies (Ter119, Gr-1, B220, and CD3) (BD Biosciences) and depleted
with anti-biotin microbeads (Miltenyi Biotech).
To create chimeric mice harboring both FLT3-ITD and WT hematopoiesis,
recipients were injected with CD45.2 FLT3-ITD and CD45.1 WT Lin cells in
a 4:1 (ITD:WT) ratio. Donor contributions were assessed by FACS posttrans-
plant (Table S4).
Sorafenib Treatment
Sorafenib was formulated and administered as previously described (Li et al.,
2011). Adult mice were orally gavaged at a dose of 10 mg/kg daily for 2 weeks356 Cell Stem Cell 11, 346–358, September 7, 2012 ª2012 Elsevier Iwith a schedule of 5 days on and 2 days off and sacrificed immediately for
analysis after the 2 week period. For functional studies after treatment, Lin
BM was isolated by magnetic cell separation as described above and
100,000 Lin cells were injected with 1 3 106 red blood cell lysed WT
CD45.1 whole bone marrow (WBM) helper cells. For the in utero experiment,
pregnant mothers were gavaged with 20 mg/kg of Sorafenib starting at
E.15 and continuing for 2 weeks after birth of pups.
Flow Cytometry and Cell Sorting
Cell preparation, staining, and analysis were performed as previously
described (Li et al., 2008). Sorting of different hematopoietic subpopulations
was also conducted on a FACS Aria (BD Biosciences) and analyzed using
FlowJo software (Flow Jo). Side population staining was conducted as previ-
ously described with Hoechst 33342 (Invitrogen) (Goodell et al., 2005) and
analyzed on a MoFlow Cytometer (Dako Cytomation).
BrdU and FLT3 Intracellular Staining
BrdU incorporation experiments were carried out using a BrdU Assay kit
(BD Biosciences) with cell surface staining prior to fixation, permeabilization,
and DNase treatment. Each of the three independent experiments was con-
ducted as per the manufacturer’s protocol.
FLT3 intracellular stains were conducted with the FoxP3/Transcription
Factor Staining Buffer set (eBioscicences). FLT3-PE antibody (BD Biosci-
ences) and PE Rat IgG2a k (BD Biosciences) isotype control was used for
these experiments.
RNA Preparation and Quantitative Polymerase Chain Reaction
RNA was isolated by using a miRNeasy Mini RNA kit (QIAGEN). cDNA
synthesis and qPCR was performed as described previously using a CFX-96
RealTime PCR system (BioRad) (Li et al., 2008). Primers for genes are listed
in the Supplemental Information (Table S4). RPS16 was used as an internal
loading control. Each PCR was run in triplicate and gene expression values
are expressed as a fold change calculated by 2DDCt. A total of three indepen-
dent PCR reactions were run for each gene target.
Statistical Analysis
All p values were calculated using a two-tailed Student’s t test with unpaired
analysis.
SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes four tables and one figure
and can be found with this article online at http://dx.doi.org/10.1016/j.stem.
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